At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 305 enrolled
Drug / intervention
rabeprazole sodium +1 moredrug
Likely dose
rabeprazole sodium 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
In Brief
A Phase 3 clinical trial evaluating rabeprazole sodium and Placebo for Symptomatic Gastroesophageal Reflux Disease (sGERD). Completed, enrolled 305 participants across 98 sites.
Detailed Summary
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJun 2009
Primary CompletionJul 2009
Study CompletionOct 2009
TodayJul 2026
First PostedJun 2, 2009
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.1 years ago
Interventions
rabeprazole sodiumdrug
One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
Placebodrug
One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.